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http://dx.doi.org/10.10Alzheimer’s disease (AD) and diabetes. Altered metabolism, inflammation, and insulin resistance are
key pathological features of both diseases. For many years, it was generally considered that the brain
was insensitive to insulin, but it is now accepted that this hormone has central neuromodulatory func-
tions, including roles in learning and memory, that are impaired in AD. However, until recently, the
molecular mechanisms accounting for brain insulin resistance in AD have remained elusive. Here, we
review recent evidence that sheds light on how brain insulin dysfunction is initiated at a molecular
level and why abnormal insulin signaling culminates in synaptic failure and memory decline. We
also discuss the cellular basis underlying the beneficial effects of stimulation of brain insulin
signaling on cognition. Discoveries summarized here provide pathophysiological background
for identification of novel molecular targets and for development of alternative therapeutic ap-
proaches in AD.
 2014 The Alzheimer’s Association. All rights reserved.Keywords: Alzheimer’s disease; Amyloid-b oligomers; Insulin resistance; Insulin therapy; GLP-1R agonists1. Introduction
Understanding the molecular basis of neuronal dysfunc-
tion and memory loss in Alzheimer’s disease (AD) has
become a major research and public health challenge
because the number of cases is predicted to increase expo-
nentially during the next few decades, and effective treat-
ments capable of halting disease progression are still
lacking [1,2]. With only a small subset of cases attributed
to inherited genetic causes [3], the mechanisms of pathogen-
esis and etiology of sporadic, late-onset AD are still not
elucidated fully. Thus, identification of molecular compo-
nents and pathways that contribute to this complex neurolog-
ical disorder has been the focus of intense research efforts
during the past few years.
Recent evidence indicates that AD is a brain-specific
form of diabetes [4,5]. The intriguing connection between
diabetes and AD was identified initially in the Rotterdamno conflicts of interest to report.
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16/j.jalz.2013.12.004study, which revealed that diabetes increases the risk of
dementia [6,7]. Subsequent clinical and epidemiologic
studies have confirmed this association (reviewed in [8])
and demonstrated that impaired metabolic parameters,
such as hyperglycemia and hyperinsulinemia, correlated
positively with development of AD-related pathology in hu-
mans [9–11]. Moreover, AD brains exhibit defective insulin
signaling, altered levels and/or aberrant activation of
components of the insulin signaling pathway, and, more
importantly, decreased responsiveness to insulin [12–14].
In peripheral tissues (e.g., liver and muscle), insulin
signaling stimulates glucose uptake and promotes metabolic
reprogramming after feeding [15]. Although the brain was
once considered an insulin-insensitive organ, and the source
of brain-acting insulin is still a matter of debate [16], it is
now established that insulin actions are important for neuronal
survival and brain function [17]. Although at that time broader
roles of brain insulin signaling were still unknown, early
studies demonstrated that insulin regulates brain metabolism
and body energy balance by acting on the hypothalamus
[18]. In addition to its role in hypothalamic metabolic control,
insulin signaling has nowbeen shown to play important roles in
other brain regions. Insulin receptors and downstreameserved.
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active in various forebrain areas important for memory forma-
tion, consolidation, and retrieval [19], including the hippocam-
pus [17]. Insulin actionswere shown recently to be required for
synaptic plasticity, learning, and memory [17,20–22].
Furthermore, in vitro and in vivo evidence supports the
notion that insulin has neuroprotective [23,24] and memory-
enhancing properties [25,26], indicating a permissive role for
insulin in cognition [27]. Thus, it is likely that defects in brain
insulin signaling may give rise to neuronal dysfunction and
cognitive deficits that are characteristic of AD.
Our understanding of the molecular underpinnings of
why AD is a memory disorder has increased significantly
during the past 15 years. For decades, it was thought that
neuritic or senile plaques, neuropathological hallmarks of
ADmainly composed of large aggregates and amyloid fibrils
of the amyloid-b (Ab) peptide, triggered neuronal death and
caused memory impairment in patients with AD [28]. How-
ever, despite the demonstrated in vitro neurotoxicity of Ab
fibrils, a puzzling observation resulting from careful neuro-
pathological examination of post mortemAD brains was that
amyloid burden did not correlate well with premortem
cognitive decline [29,30]. Instead, those studies showed
that cognitive deficits were highly correlated with synapse
loss [30–32], and suggested that an as-yet-unidentified toxin,
but not amyloid plaques, was responsible for triggering
memory loss in AD. Identification of soluble amyloid-b
oligomers (AbOs) as synaptotoxins that accumulate in AD
brains [33–36] stimulated a paradigm shift in the field,
with AbOs now considered the proximal toxins
responsible for synapse dysfunction and memory failure in
AD (for recent reviews, see [1,37–39]).
In the following sections, we review recent findings linking
the neurotoxic impact of AbOs and defects in brain insulin
signaling in AD. Because these data indicate a close similarity
between pathways that drive peripheral insulin resistance in
diabetes and brain insulin dysfunction in AD, we summarize
further and discuss the molecular bases for using antidiabetic
agents as novel therapeutic approaches in AD.2. Deregulated brain insulin signaling in AD
In peripheral metabolic disorders, such as type 2 diabetes,
prolonged metabolic stress and proinflammatory signaling
lead to attenuated insulin signaling and decreased cellular
responsiveness to insulin [40]. This pathological state is
referred to as insulin resistance and it impairs acutely the
ability of cells to maintain energy homeostasis. Interestingly,
AD brains present similar abnormalities, including meta-
bolic stress and neuroinflammation [12–14,41–43]. Thus,
it is conceivable that similar mechanisms account for
peripheral insulin resistance in type 2 diabetes and
impaired brain insulin signaling in AD. Indeed, recent
studies have linked neuropathogenic mechanisms triggered
by AbOs to mechanisms involved in peripheral insulin
resistance in diabetes [41,44,45].Physiologically, insulin binds to its cell surface receptor
(insulin receptor [IR]) and triggers intrinsic IR tyrosine ki-
nase activity. Activated IRs then phosphorylate members
of a conserved family of adaptor proteins called insulin re-
ceptor substrates 1 through 4 (IRS-1 through IRS-4) [15].
Once phosphorylated at tyrosine residues, IRS proteins act
as scaffolds that couple IR stimulation to downstream effec-
tors, such as phosphoinositide 3-kinase (PI3K), murine thy-
moma viral oncogene homolog (or Akt)/protein kinase B,
and mammalian target of rapamycin complex 1 [15], allow-
ing metabolic and transcriptional reprogramming of cells
[46]. On the other hand, IRS-1 and IRS-2, the best-studied
components of the IRS family, can undergo inhibitory serine
phosphorylation (pSer), which causes their dissociation
from the IR and decreases tyrosine phosphorylation (pTyr)
[46]. Therefore, an intricate balance between IRS phosphor-
ylation at serine or tyrosine residues (IRS-1pSer vs. IRS-
1pTyr) determines the extent of insulin actions [47].
In type 2 diabetes, aberrant tumor necrosis factor-a (TNF-
a) signaling leads to activation of the stress kinase c-Jun N-
terminal kinase (JNK) [48]. Activated JNK phosphorylates
IRS-1 at serine residues (IRS-1pSer), blocking downstream
insulin signaling and causing peripheral insulin resistance
[40]. Similarly, it was shown recently that AbOs instigate
aberrant activation of the TNF-a/JNK pathway and IRS-1 in-
hibition in primary hippocampal neurons [41,44], and in the
hippocampi of cynomolgus monkeys that received
intracerebroventricular infusions of AbOs [41]. IRS-1 inhibi-
tionwas also demonstrated in the brains of a transgenicmouse
model of AD [41]. Most important in establishing the clinical
relevance of these findings was the demonstration of elevated
IRS-1pSer [14,41] and activated JNK [41] in postmortem AD
brains. Because AbOs trigger internalization and redistribu-
tion of neuronal IRs [49], it is possible that removal of IRs
from the cell surface facilitates IRS-1pSer, a view that is
consistent with our finding that insulin blocks both neuronal
IR downregulation [50] and IRS-1pSer induced byAbOs [41].
Downstream from IRS-1 and PI3K, AbOs instigate
Ser473 phosphorylation of Akt, a molecular hub in the insu-
lin signaling pathway. Elevated pSer473 levels are associ-
ated with feedback-dependent Akt inhibition in
inflammation and peripheral insulin resistance [51,52].
Interestingly, induction of Akt-pSer473 by AbOs takes place
both in the absence and presence of insulin [49], suggesting
that it could be mediated by an IR-independent pathway,
likely involving TNF-a signaling.
In peripheral insulin resistance, activation of the TNF-a/
JNK pathway is linked to major inflammatory/stress
signaling networks, including endoplasmic reticulum (ER)
stress and the stress kinases IkBa kinase (IKK) and double-
stranded RNA-dependent protein kinase (PKR) [53,54]. We
recently reported that IkBa kinase and double-stranded
RNA-dependent protein kinase appear to mediate AbO-
induced IRS-1 inhibition in hippocampal neurons [41]. It is
also conceivable that ER stress, which has been reported in
AD brains [43,55], further underlies oligomer-induced
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to be the case, this would reinforce the notion that common
mechanisms underlie impaired peripheral insulin signaling
in type 2 diabetes and brain insulin resistance in AD [41].3. A possible crosstalk between deregulated insulin and
N-methyl-D-aspartate receptor signaling
AbOs have been documented to cause aberrant activation
and deregulation of N-methyl-D-aspartate (NMDA)-subtype
glutamate receptors (NMDARs) [56–59]. Deregulated
NMDAR function may play a role in the impairment of
neuronal insulin signaling in AD, because AbO-induced
inhibition of IR signaling is prevented by the NMDAR
blocker memantine [49]. Both memantine and an antibody
against the constitutive NMDAR subunit 1 (or GluN1) atten-
uate the rapid increase in intraneuronal calcium and neuronal
oxidative stress triggered by AbOs [56,58]. Because
excitatory glutamate signaling and neuronal depolarization
reduce the responsiveness of IRs to insulin [49], and chelation
of intracellular calcium with BAPTA-AM prevents both
AbO-induced IR inhibition [49] and oxidative stress [56], it
seems plausible that a mechanism involving aberrant
NMDAR-dependent calcium influx underlies neuronal insu-
lin resistance in AD.
Under physiological conditions, synaptic NMDAR activ-
ity exerts an antioxidant role through suppression of the
FOXO1 transcription factor in the hippocampus [60,61]. In
AD, however, abnormal NMDAR function and insulin
resistance may enable nuclear translocation of FOXO1,
culminating in increased generation of reactive oxygen
species and, possibly, activation of stress kinases [62].
This, in turn, may exacerbate the impairment of insulin
signaling and neuronal dysfunction.
Another possibility is that excessive NMDAR activation
and calcium influx triggered by oligomers [57,58,63,64]
stimulate the activity of tyrosine phosphatases on IRS-1,
as described for glutamate-induced neuronal damage [65],
thus attenuating insulin signal transduction. These possibil-
ities are in harmony with described IR regulatory mecha-
nisms and suggest a possible physiological feedback
between deregulated neuronal activity and insulin signaling.
A schematic outline of this interplay under physiological
and pathological conditions is presented in Fig. 1.
Interestingly, defective insulin signaling accelerates
Ab production in the brain by enhancing the
amyloidogenic processing of the amyloid precursor
protein [66,67], and also increases Ab aggregation through
monosialotetrahexosylganglioside (GM1) clustering and
membrane signaling [68]. Thus, oligomer-induced insulin
resistance may create a vicious cycle in which oligomers up-
regulate their own production and aggregation by disrupting
insulin physiological actions. Such a mechanism could ac-
count in part for AbO buildup in AD brains.
In summary, multiple toxic effects of AbOs may impair
proper brain insulin signaling and trigger a feed-forwardcascade that disrupts neuronal functions through increased
cellular stress (e.g., aberrant cytosolic calcium, oxidative
stress, ER stress). This condition, in turn, appears to inten-
sify neuronal insulin resistance and Ab generation. Because
defective neuronal IR/IRS-1 function appears critical for the
onset of AD-related neuronal damage, it seems likely that
bolstering insulin sensitivity and actions could provide
encouraging results in preventing/rescuing memory decline.4. Stimulation of brain insulin signaling as a novel
therapeutic approach in AD
Our understanding of how sporadic AD develops has
increased significantly during the past few years. For
example, it is now well established that the onset of AD cor-
relates with synapse failure and metabolic changes in the
brain [28]. Moreover, accumulation of soluble Ab species,
notably oligomers, likely accounts for altered brain function
[28]. To date, however, most approaches proposed as possible
treatments for AD have failed disappointingly in clinical trials
[1]. At the same time, insulin-based strategies have emerged
as potentially successful therapies for AD [45].
Brain insulin signaling declines with age [69], the major
risk factor for AD, suggesting that restoring insulin signaling
might be beneficial to patients with AD. Of special interest is
the finding that intranasal insulin administration, a preferen-
tial route for central nervous system delivery [70], improves
memory in healthy adults without affecting circulating
levels of insulin or glucose [25,71]. Intranasal insulin also
enhanced verbal memory in memory-impaired subjects
[72] and improved cognitive performance in patients with
early AD [45,73]. In this regard, it is noteworthy that a
larger scale clinical trial is now planned to determine the
efficacy of insulin in improving memory and cognition in
patients with AD [74]. The mechanism of neuroprotection
by insulin appears to involve downregulation of neuronal
AbO binding sites [50] and increased oligomer clearance
[75], consequently preventing IR internalization and syn-
apse loss [50,76,77]. Insulin-mediated synapse protection
mechanisms could thus contribute to preserved cognitive
function in normal individuals, whereas impaired insulin
signaling might render neurons vulnerable to oligomer-
induced synaptotoxicity. As pointed out recently, insulin
may have important therapeutic implications at early and/
or intermediate phases of AD [72,78], preventing oligomer
binding to synapses and blocking insulin receptor
pathology [13,49,50]. At later disease stages, when surface
IRs dwindle, it is possible that insulin may stimulate other
receptors (e.g., insulin-like growth factor 1 (IGF-1)
receptors) and thus still improve AD-related deficits.
Alternative approaches to boost insulin-related signaling
pathways might provide additional therapeutic opportunities
in AD [79,80]. In this regard, glucagon-like peptide 1
receptor (GLP-1R) agonists are an attractive option
because they activate pathways common to insulin
signaling and facilitate hippocampal synaptic plasticity,
Fig. 1. Impaired neuronal insulin signaling in Alzheimer’s disease (AD). Schematic outline of neuronal insulin signaling in normal brain (left) and AD brain
(right). Under physiological conditions, insulin binding to its cell surface receptor (insulin receptor [IR]) triggers IR autophosphorylation and subsequent tyro-
sine phosphorylation of insulin receptor substrate 1 (IRS-1). This results in phosphoinositide 3-kinase (PI3K) activation and downstream cellular responses that
facilitate synaptic plasticity and memory. Activity-dependent calcium (Ca21) influx via N-methyl-D-aspartate receptors (NMDARs) activates signaling and
expression of genes involved in synaptic plasticity and memory. A crosstalk between NMDAR- and IR-dependent signaling maymodulate the actions of insulin
on memory. In AD, accumulation of amyloid-b (Ab) oligomers leads to increased tumor necrosis factor-a (TNF-a) levels and activation of stress kinases (c-Jun
N-terminal kinase [JNK], double-stranded ribonucleic acid [RNA]-dependent protein kinase [PKR], and IkBa kinase [IKK]), resulting in inhibitory serine phos-
phorylation of IRS-1. Ab oligomers instigate additional removal of IRs from the cell surface and redistribution to the cell body. These combined events block
neuronal insulin signaling. Aberrant activation of NMDARs byAb oligomers results in excessive Ca21 influx, neuronal oxidative stress, and disrupted signaling,
leading to impaired synaptic plasticity. Under these conditions, putative activation of protein tyrosine phosphatases may inhibit IRS-1 signaling further, ulti-
mately leading to synapse impairment and memory failure. pSer, phosphoserine; pTyr, phosphotyrosine; TNFR, TNFa receptor.
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liraglutide are two such agonists that have been approved
for treatment of type 2 diabetes. GLP-1 analogs are stable
in blood and exhibit good brain penetration [85]. Exendin-
4 was found recently to block AbO-induced impairment in
insulin signaling in hippocampal neurons [41]. Exendin-4
also restored impaired brain insulin signaling in a transgenic
mouse model of AD, decreasing Ab accumulation and
improving cognition [41]. More significant, liraglutide has
been shown to counteract Ab-induced memory deficits in
mice [86] and to reduce neuropathology and improve cogni-
tive performance in AD transgenic mice [87].
The complete cellular machinery recruited by GLP-1R
activation to mediate neuroprotection and cognitive
enhancement is still not fully understood, but the recent
finding that exendin-4 reduces JNK activation and improves
insulin signaling in an AD mouse model provides initial
clues on this issue [41]. One may further speculate that neu-
roprotection involves both cyclic adenosine monophosphate
(cAMP) production and PI3K activation, mechanisms that
ultimately favor neuronal survival, enhanced synaptic plas-
ticity, and memory formation. GLP-1R activation may thus
provide a novel strategy to resensitize impaired brain insulin
signaling and to prevent or halt neurodegeneration in AD.5. Conclusions
AD is still a disorder in search of mechanisms that fully
explain memory loss and lead the way to development ofeffective therapies. Recent reports demonstrating shared
clinical and pathophysiological traits between AD and dia-
betes raise the possibility that antidiabetic agents might pro-
vide cognitive benefit. This notion finds support in evidence
that AbOs, increasingly viewed as key synaptotoxins in AD,
disrupt normal brain insulin signaling via proinflammatory
mechanisms, similar to what happens in peripheral tissue
in diabetes. The resulting scenario of cellular stress and syn-
apse dysfunction appears to be counteracted by stimulating
brain insulin signaling, either using insulin itself or antidia-
betic drugs such as GLP-1R agonists.
In conclusion, establishing a molecular link between AD
and diabetes may have important implications for eluci-
dating the mechanisms underlying neuronal dysfunction in
AD. It is conceivable that novel therapeutic options for
AD may arise from efforts aimed at unraveling mechanisms
accounting for brain insulin resistance [45,73]. We look
forward to results from recently implemented clinical trials
using both insulin [88] and GLP-1R agonists [89,90] in
AD. Hopefully, results from those trials will favor the
emergence of novel therapeutic opportunities for this
devastating disease.Acknowledgments
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